Literature DB >> 22187700

Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients.

Tamás Molnár1, Klaudia Farkas, Tibor Nyári, Zoltán Szepes, Ferenc Nagy, Tibor Wittmann.   

Abstract

BACKGROUND AND AIMS: A severe flare-up develops in approximately 15% of patients with ulcerative colitis (UC). It is questionable whether the response to the first parenteral corticosteroid therapy decreases the risk for colectomy. Our aim was to evaluate the association between long-term colectomy rate and the efficacy of steroids in the first few days of the therapy and to assess other predictive factors for colectomy in our patients hospitalized because of the first severe attack of UC. PATIENTS AND METHODS: The records of the first hospitalization of a total of 183 UC patients with severe exacerbation were reviewed. Every patient had received parenteral corticosteroid treatment. Colectomy was performed in refractory UC or in the case of intolerable side-effects of the rescue therapy. We compared different laboratory and clinical parameters between patients undergoing colectomy and those who avoided surgery.
RESULTS: Clinical response to steroid therapy was achieved in 110 of the 183 patients with acute severe UC; 14.5% of steroid responder patients were operated on during the follow-up period. 39.7% of patients in the steroid-refractory group required either urgent or late colectomy. The overall colectomy rate was 24.6%. Unresponsiveness to intravenous steroid therapy, anemia, and the need for blood transfusion proved to be the major predictors for colectomy.
CONCLUSION: The colectomy rate was 2.5 times higher in our patients with acute severe UC not responding to the intensive steroid therapy, suggesting that the response to the therapy of the first 3-5 days of hospitalization may determine the long-term outcome and colectomy rate in UC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22187700

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  11 in total

Review 1.  Acute severe ulcerative colitis: from pathophysiology to clinical management.

Authors:  Pieter Hindryckx; Vipul Jairath; Geert D'Haens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

2.  Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience.

Authors:  Tarun Rai; Bikash Narayan Choudhury; Saurabh Kedia; Sawan Bopanna; Pratap Mouli Venigalla; Sushil Kumar Garg; Vikas Singla; Govind Makharia; Vineet Ahuja
Journal:  Dig Dis Sci       Date:  2017-02-04       Impact factor: 3.199

3.  Long-term outcome of cyclosporin rescue therapy in acute, steroid-refractory severe ulcerative colitis.

Authors:  Tamás Molnár; Klaudia Farkas; Zoltán Szepes; Ferenc Nagy; Mónika Szűcs; Tibor Nyári; Anita Bálint; Tibor Wittmann
Journal:  United European Gastroenterol J       Date:  2014-04       Impact factor: 4.623

Review 4.  The Management of the Hospitalized Ulcerative Colitis Patient: the Medical-Surgical Conundrum.

Authors:  Michele Carvello; Joseph Watfah; Marcin Włodarczyk; Antonino Spinelli
Journal:  Curr Gastroenterol Rep       Date:  2020-02-10

5.  Novel treatment options for ulcerative colitis.

Authors:  Byron P Vaughn; Alan C Moss
Journal:  Clin Investig (Lond)       Date:  2013-11

Review 6.  Epidemiology of Inflammatory Bowel Disease in India: The Great Shift East.

Authors:  Saurabh Kedia; Vineet Ahuja
Journal:  Inflamm Intest Dis       Date:  2017-04-08

7.  A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares.

Authors:  Parambir S Dulai; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2020-11-13       Impact factor: 3.487

Review 8.  Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?

Authors:  Abhinav Vasudevan; Peter R Gibson; Daniel R van Langenberg
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

9.  Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice.

Authors:  Shomron Ben-Horin; Jane M Andrews; Konstantinos H Katsanos; Florian Rieder; Flavio Steinwurz; Konstantinos Karmiris; Jae Hee Cheon; Gordon William Moran; Monica Cesarini; Christian D Stone; Doron Schwartz; Marijana Protic; Xavier Roblin; Giulia Roda; Min-Hu Chen; Ofir Har-Noy; Charles N Bernstein
Journal:  World J Gastroenterol       Date:  2017-04-28       Impact factor: 5.742

10.  The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis.

Authors:  Desmond Patrick; James Doecke; James Irwin; Katherine Hanigan; Lisa Simms; Mariko Howlett; Graham Radford-Smith
Journal:  Therap Adv Gastroenterol       Date:  2018-11-13       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.